Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VREX vs DCTH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DCTH Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 3–7 Matrix Metrics)

DCTH Overall Winner 6-Pillar Tally: VREX 1 – 5 DCTH Matrix Metrics: VREX 7 – 3 DCTH

As of Nov 16, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over Varex Imaging Corporation (VREX) in the Tradestie Institutional Equity Comparison Engine, winning 3–7 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). VREX carries a Unified Composite Score of 50.0/100 (HOLD) at $18.21 (16.9x Forward P/E, 8.3% operating margin), whereas DCTH carries 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin).

  • Composite vs. Pillar Nuance: While VREX currently prints a higher short-term Unified Composite Score (50.0/100 HOLD vs. DCTH 35.9/100 SELL), DCTH captures the overall institutional head-to-head verdict (3–7 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (5.2% vs. 8.3% operating margin) and revenue trajectory (+70.7% vs. +3.7% YoY).
  • Technical & Structure Timing Caution: VREX is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 35.5); meanwhile DCTH trades in a Neutral technical trend (BREAKOUT options phase, RSI 68.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VREX vs DCTH
VREX NASDAQ
Varex Imaging Corporation Common Stock
Electronic Components, Nec
$18.21
+0.64% 1D
Market Cap $771.6M
TTM Revenue $865M
Forward P/E 16.9x
Beta / 30D Vol 0.74β · 5% Vol
Unified Composite Score
50.0 / 100 HOLD
Tech 47.0 Fund 50.0 Flow 50.0 Mom 56.1
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -0.2%) with fading momentum, RSI 36
RSI-14: 35.5 · SMA20: $18.40 · SMA50: $18.44
DCTH NASDAQ Head-to-Head Winner
Delcath Systems Inc
Surgical & Medical Instruments & Apparatus
$19.68
-4.23% 1D
Market Cap $743.8M
TTM Revenue $110M
Forward P/E N/M
Beta / 30D Vol 1.63β · 131% Vol
Unified Composite Score
35.9 / 100 SELL
Tech 50.0 Fund 38.0 Flow 60.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 69
RSI-14: 68.9 · SMA20: $16.43 · SMA50: $15.96

6-Pillar Scorecard Institutional Category Breakdown (VREX 1 – 5 DCTH)

Columns: Metric · VREX · DCTH
1. Valuation Multiples VREX
Forward P/E 16.9x N/M
Trailing P/E 34.3x 133.6x
PEG Ratio 6.30x 1.60x
EV / Revenue 0.9x 6.3x
2. Growth & Scale DCTH
Revenue Growth (YoY) +3.7% +70.7%
Earnings Growth (YoY) +453.4% +750.0%
TTM Revenue (USD) $865M $110M
Market Cap $771.6M $743.8M
3. Profitability & Quality DCTH
Gross Margin 34.3% 87.6%
Operating Margin 8.3% 5.2%
Net Profit Margin 2.6% 6.0%
Return on Equity (ROE) 4.6% 5.4%
4. Balance Sheet & Cash Flow DCTH
Cash Generation (TTM) $100M EBITDA $20M
Cash Flow Margin 11.5% EBITDA Mgn 18.3%
Net Cash / Leverage $11.78 Book/Sh · 4.6% ROE $53M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DCTH
Options Structure Phase UNCLASSIFIED BREAKOUT
Current IV / %ile 112.0% (18th %ile) 109.3% (43rd %ile)
Put/Call OI Skew N/A 0.11x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Distribution ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat DCTH
OpEx & R&D Intensity 26.0% of Rev ($225M) 82.4% of Rev ($91M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VREX (7) vs DCTH (3)
Institutional Metric VREX DCTH Criterion Row Edge
Market Capitalization
Scale
$771.6M $743.8M Larger Scale VREX
Trailing P/E Ratio
Valuation
34.3x 133.6x Lower Multiple VREX
Forward P/E Ratio
Valuation
16.9x N/M Lower Multiple VREX
Revenue Growth (YoY)
Growth
+3.7% +70.7% Higher Growth DCTH
Operating Margin (TTM)
Profitability
8.3% 5.2% Higher Margin VREX
Net Profit Margin
Profitability
2.6% 6.0% Higher Margin DCTH
Return on Equity (ROE)
Capital Efficiency
4.6% 5.4% Higher ROE DCTH
52-Week Range Position
Momentum
96% ($9–$19) 80% ($8–$23) Stronger Trend VREX
Beta / 30D Volatility
Risk Regime
0.74β · 5% Vol 1.63β · 131% Vol Lower Realized Risk VREX
Unified Institutional Score
Composite Signal
50.0 / 100 (HOLD) 35.9 / 100 (SELL) Higher Composite VREX
Trailing 12M Revenue (USD)
Operating Scale
$865M $110M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
34.3% 87.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
6.30x PEG · 0.9x EV/Rev 1.60x PEG · 6.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$100M EBITDA ($11.78 Book/Sh · 4.6% ROE) $20M ($53M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DCTH +40.83 pp
VREX: -1.06% · DCTH: +39.77%
3M Horizon DCTH +18.06 pp
VREX: -1.33% · DCTH: +16.73%
6M Horizon VREX +10.32 pp
VREX: +87.78% · DCTH: +77.46%
1Y Horizon DCTH +77.03 pp
VREX: +51.54% · DCTH: +128.57%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VREX vs DCTH. Trailing 12-month operating profitability (VREX 8.3% vs DCTH 5.2%) and valuation multiples (VREX 16.9x vs DCTH N/M Forward P/E) are benchmarked directly in Pillar 4 below.

VREX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$865M
Gross Margin34.3%
Op. Margin8.3%
ROE / Fwd P/E4.6% · 16.9x
DCTH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$110M
Gross Margin87.6%
Op. Margin5.2%
ROE / Fwd P/E5.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VREX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 112.0%
IV Percentile 18th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VREX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DCTH BREAKOUT
66d in phase · OBV ACCUMULATION
Current IV 109.3%
IV Percentile 43rd %ile
Put/Call OI Skew 0.11x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact DCTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VREX Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $771.6M market capitalization and 8.3% operating margin.
OpEx & R&D Reinvestment 26.0% of Rev ($225M)
90D Engineering Disclosures 0 Published
DCTH Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $743.8M market capitalization and 5.2% operating margin.
OpEx & R&D Reinvestment 82.4% of Rev ($91M)
90D Engineering Disclosures 0 Published

Investor FAQ VREX vs DCTH Key Questions & Quantitative Answers

As of Nov 16, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over Varex Imaging Corporation (VREX) in the Tradestie Institutional Equity Comparison Engine, winning 3–7 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). VREX carries a Unified Composite Score of 50.0/100 (HOLD) at $18.21 (16.9x Forward P/E, 8.3% operating margin), whereas DCTH carries 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin). Composite vs. Pillar Nuance: While VREX currently prints a higher short-term Unified Composite Score (50.0/100 HOLD vs. DCTH 35.9/100 SELL), DCTH captures the overall institutional head-to-head verdict (3–7 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (5.2% vs. 8.3% operating margin) and revenue trajectory (+70.7% vs. +3.7% YoY). Technical & Structure Timing Caution: VREX is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 35.5); meanwhile DCTH trades in a Neutral technical trend (BREAKOUT options phase, RSI 68.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DCTH leads the Growth & Scale pillar: VREX posts +3.7% YoY revenue growth and +453.4% YoY earnings growth on $865M TTM revenue (34.3% gross margin, 8.3% operating margin), compared with DCTH at +70.7% YoY revenue growth and +750.0% YoY earnings growth on $110M TTM revenue (87.6% gross margin, 5.2% operating margin). On trailing 12-month operating scale, VREX generates $865M in USD-normalized revenue versus $110M for DCTH. In operating R&D and SG&A reinvestment, VREX deploys 26.0% of Rev ($225M) (0 90-day corporate R&D disclosures) versus 82.4% of Rev ($91M) (0 disclosures) for DCTH.

VREX screens cheaper on headline valuation multiples. VREX trades at 16.9x Forward P/E, 34.3x Trailing P/E, 6.30x PEG, and 0.9x EV/Revenue (11.5% EBITDA margin), whereas DCTH trades at N/M Forward P/E, 133.6x Trailing P/E, 1.60x PEG, and 6.3x EV/Revenue (18.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VREX (4.6% ROE) versus DCTH (5.4% ROE) capital efficiency.

In options market volatility and institutional positioning, VREX carries 112.0% implied volatility (18th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.74β · 5% Vol realized risk). By comparison, DCTH carries 109.3% implied volatility (43rd %ile, Balanced (25th–60th %ile)), a 0.11x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.63β · 131% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.